Infectious Disease Control

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

* In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). * The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in pati...

2022-06-13 21:20 2780

EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

PROVIDENCE, R.I., June 11, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces that it has developed VennVax,a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R4...

2022-06-11 03:15 6165

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections inChina Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resoluti...

2022-06-09 19:00 2609

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

* Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee * If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine availa...

2022-06-08 09:23 2401

Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future

NANJING, China, June 2, 2022 /PRNewswire/ -- Vazyme, China's leading biotechnology company, has recently released its 2021 annual report, revealing that the company has maintained a steady and solid growth throughout the past year. The report shows that it has achieved$289 million in operating in...

2022-06-02 12:54 2871

Kemin Food Technologies - Asia Introduces Antimicrobial Disinfectant Solutions KEEPER™ and OXINE™

Latest product lines address safety at the start by treating food, water and the preparation space for food SINGAPORE, June 1, 2022 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world w...

2022-06-01 08:00 2752

Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy

TAIPEI, May 27, 2022 /PRNewswire/ -- Taiwanese biotech outfit AcadeMab has broken new ground in the development of COVID immunotherapies through the development of a potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology, shows the best neutralization a...

2022-05-27 11:40 2746

ScentAir Steps Up Efforts to Address Customers' Concern Over Air Quality

HONG KONG, May 26, 2022 /PRNewswire/ -- ScentAir, the scent marketing leader, continues to lead the way in helping brands globally address customers' concerns, as cases surge inChina amid lockdowns.

2022-05-26 17:26 2913

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 2171

Brii Biosciences to be Added to MSCI China Small Cap Index

DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as ofHong Kong market close on May 31, 2022. ...

2022-05-25 08:00 4303

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. Insi...

2022-05-24 21:00 2439

New Study Shows Critical Role of 1,5-Anhydroglucitol (1,5-AG) in COVID-19 Pathogenesis by Binding to the COVID-19 Spike Protein

Study Findings Support Data Presented on the GlycoMark Blood Test at the Most RecentADA and AHA Scientific Sessions  RALEIGH, N.C., May 24, 2022 /PRNewswire/ -- Precision Diabetes, Inc. A new study recently published inNature Metabolism shows that 1,5-anhydroglucitol (1,5-AG), a glucose-like me...

2022-05-24 19:00 1489

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...

2022-05-19 23:28 3425

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...

2022-05-19 04:56 2579

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096)  announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute ofMateria Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinica...

2022-05-18 11:56 1994

ASEAN to build its own CDC to mitigate another pandemic risk

DENPASAR, Indonesia, May 18, 2022 /PRNewswire/ -- ASEAN members agreed on setting up the ASEAN Center for Public Health Emergencies and Emerging Diseases (ACPHEED) at the 15th ASEAN Health Minister Meeting (15th AHMM)  inNusa Dua, Bali, Indonesia on May 11-15, 2022.

2022-05-18 09:00 2745

ASEAN accepts mutually recognized COVID-19 vaccination certificates

DENPASAR, Indonesia, May 17, 2022 /PRNewswire/ -- ASEAN Member States collectively recognize the COVID-19 vaccination certificate to be applied in Southeast Asia. Health Ministers of ASEAN countries endorsed the decision during the 15th ASEAN Health Ministers Meeting (15th AHMM) inNusa Dua, Bali, ...

2022-05-17 19:14 1969

NEW GUIDELINES FOR COVID TESTING

A new ISO technical specification will improve testing procedures and contribute to a safer world. SHENZHEN, China, May 13, 2022 /PRNewswire/ -- The COVID pandemic first reared its head in 2019 and despite concerted efforts from authorities and the public, it's still with us. Dedicated stan...

2022-05-13 17:10 2036

ECCMID 2022: Copan unveils its WISE approach to sample management

BRESCIA, Italy, May 12, 2022 /PRNewswire/ -- Copan took the chance of the first in-person ECCMID of the last two years to give a name to itsholistic approach to preanalytics. From sample collection to image analysis and data interpretation, meet Copan's WISE approach, which brings any sample to i...

2022-05-12 20:25 2046

HKBN Receives Amazon Web Services' HK Managed Service Award

Cloud technology enhances scalability and flexibility HONG KONG, May 11, 2022 /PRNewswire/ -- HKBN Enterprise Solutions ("HKBN") is awardedAmazon Web Services' ("AWS") Managed Service Provider Partner of the Year . With the largest number of AWS certifications inHong Kong, HKBN is actively embrac...

2022-05-11 11:49 2525
1 ... 891011121314 ... 65

Week's Top Stories